remestemcel-L has NOT been rejected by the F
DA. A CRL is in fact "approved if you meet condition X". Unlike Regenaron it has a flawless safety profile. Regenaron is on a phase 1/2/3 trial and needs to meet the endpoints for each phase. It looks good so far, but is for a different stage of the disease and largely unrelated to us. It is not a revolutionary new way to treat inflammatory disease and therfore is indeed not in same league as MSB's products.
remestemcel-L has NOT been rejected by the FDA. A CRL is in fact...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.070(6.45%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.20 | $1.11 | $20.88M | 17.94M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 59978 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 34019 | 3 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
0.070 ( 5.63 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.20 | $1.12 | 3733217 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| MSB (ASX) Chart |